Immunocore (IMCR) Fundamental Analysis: Revenue, Earnings & Valuation

2.14 / 10

Underperform

Fundamental rating is Underperform with a 2.1/10 score. Cash‑MV and gross profit margin are decent, but PB‑ROE, Revenue‑MV and income‑tax ratios are weak, indicating constrained earnings and valuation concerns.

Analysis Checks(7/10)

Revenue-MV

Value-0.77

Score1/3

Weight20.07%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value28.95

Score3/3

Weight5.19%

1M Return1.54%

Inventory turnover ratio

Value0.83

Score2/3

Weight-3.74%

1M Return-1.21%

Gross profit margin (%)

Value98.73

Score2/3

Weight6.07%

1M Return1.69%

PB-ROE

Value0.54

Score0/3

Weight13.40%

1M Return3.23%

Income tax / Total profit (%)

Value-85.94

Score1/3

Weight-1.54%

1M Return-0.50%

Fixed assets turnover ratio

Value37.12

Score2/3

Weight-1.77%

1M Return-0.51%

Cost of sales ratio (%)

Value1.27

Score2/3

Weight-12.79%

1M Return-4.42%

Asset-MV

Value-0.55

Score2/3

Weight51.47%

1M Return12.22%

Cash-MV

Value0.02

Score2/3

Weight23.65%

1M Return5.94%

Is IMCR fundamentally strong?

IMCR scores 2.14/10 on fundamentals and holds a Premium valuation at present. Backed by its -9.58% ROE, -8.88% net margin, -44.01 P/E ratio, 4.10 P/B ratio, and 30.39% earnings growth, these metrics solidify its Underperform investment rating.